SEKISUI: Enhancement Of Medical Business In China

Date: 3 March 2010
Source: SEKISUI
The High Performance Plastics Company (President: Takayoshi Matsunaga) of SEKISUI CHEMICAL CO., LTD. (President: Naofumi Negishi, hereinafter Sekisui Chemical) has announced plans to merge two subsidiaries related to medical business in China, in order to enhance business in that market.  1.

Background
Until now, BEIJING SEKISUI TRANK MEDICAL TECHNOLOGY CO., LTD. (hereinafter Sekisui Trank) has handled business development in China in the area of vacuum blood collection tubes, and SHANGHAI DAIICHI DIAGNOSTICS, CO., LTD. (hereinafter Shanghai Daiichi) has handled business development in China in the area of clinical reagents.
 
Sekisui Trank, established as a joint venture with a Chinese firm, manufactures and sells vacuum blood collection tubes. In addition to its plant in Beijing, it also has sales facilities located across China, and it is achieving steady sales growth including exports to Asian markets.
 
Shanghai Daiichi provides support for the activities of sales agents in China for reagents exported by SEKISUI MEDICAL CO., LTD. (hereinafter Sekisui Medical). Against a background of a growing Chinese market for reagents, in recent years the value of exports has continued to increase from year to year.
 
2. Outline of this merger
With this merger, Shanghai Daiichi will be merged into Sekisui Trank, to form a major facility in the Chinese market. Plans call for the merger procedures to be completed in September of this year.
 
Also, plans call for the Sekisui Trank plant that currently produces vacuum blood collection tubes to begin production of clinical reagents as well following the merger.
 
Also, in advance of this merger Sekisui Chemical accepted transfer in December of last year of a 15% of equity stake held by a Chinese joint-venture partner of Sekisui Trank, increasing its stake in the company from 85% to 100%. Furthermore, in February of this year the name of Sekisui Trank was changed to SEKISUI MEDICAL TECHNOLOGY (CHINA) LTD., to develop a unified brand image and increase its presence in the medical industry in China.
 
Read more here.

600450 SEKISUI: Enhancement Of Medical Business In China glassonweb.com

See more news about:

Others also read

LandGlass Won the Silver Award at “The Third China Dual-use Technological Innovation Application Contest”.
The 2019 exhibition will be held in Guangzhou-Pazhou-Canton Fair from August 22nd to 24th.
Recently, LandGlass was named as one of the “Outstanding Private Enterprises in Luoyang - High Growth Innovative Entities” by the CPC Luoyang Municipal Committee and the People’s Government of Luoyang Municipality.
On November 22, the municipal office of civilization and office of credibility held the “2018 Credible Private Enterprises” commendation conference at the 2nd floor conference room of the Luoyang city hall.
Permasteelisa S.p.A welcomes the LIXIL Group Corporation’s announcement about the agreement with Grandland Holdings Group Limited, a leading Chinese architectural design and construction company, to terminate planned Permasteelisa transaction.
Asia’s No. 1 fenestration exhibition - FENESTRATION BAU China 2018 (”FBC”) concluded on November 3, 2018 in Beijing.

From industry

No. 160 Yichuan Rd.,
Jiaonan Shi
Qingdao Shi
Shandong Sheng, 266000
China

Add new comment